Gerresheimer's Critical Juncture: Rejecting a Suitor to Tackle Internal Turmoil

Gerresheimer AG rejects a takeover offer, battles an accounting probe delaying audited results, and restructures debt while selling a US unit to stabilize its finances.

Gerresheimer AG finds itself at a pivotal moment, having just spurned a takeover bid while racing to resolve a deep-seated accounting crisis. The Düsseldorf-based packaging specialist recently rejected an unsolicited, non-binding offer of 41 euros per share from US rival Silgan Holdings, signaling that internal restructuring takes precedence over a sale.

The decision comes as the company grapples with severe pressure on multiple fronts. Its shares, which fell to around 21.00 euros on Monday, have lost more than 24 percent since the start of the year, reflecting extreme market volatility. A significant driver of this weakness is aggressive short-selling activity, with transparency reports showing a marked increase in bearish bets by professional speculators.

These short-sellers are exploiting a critical vulnerability: Gerresheimer has yet to publish its audited financial statements for the past two years. This lack of certified numbers leaves investors in the dark and makes any serious fundamental valuation nearly impossible. Analysts at Bernstein Research have explicitly warned of this accounting risk. The delay stems from a widened regulatory probe by German watchdog BaFin, which is examining irregularities related to "bill-and-hold" transactions where revenue may have been booked prematurely. External auditors are also scrutinizing potential impairments at the Swiss subsidiary Sensile Medical.

The fallout from the accounting delay has been concrete. On April 10, Gerresheimer was ejected from the SDAX index because it failed to meet the Deutsche Börse's requirement to publish annual results within four months of the fiscal year-end.

To stabilize its financial position, the company has secured crucial breathing room from its creditors. An overwhelming majority of bondholders agreed to an extension, meaning the audited consolidated financial statements for 2025 are now due by the end of September. This agreement provides significant relief for day-to-day operations, as lenders have waived compliance with key financial covenants through the third quarter. Management, however, is targeting an even more ambitious timeline, aiming to have the audited reports ready by June.

Concurrently, Gerresheimer is pushing ahead with the sale of its US subsidiary Centor Inc. to reduce debt. The divestment process is already in full swing, with a double-digit number of interested parties currently conducting due diligence, according to experts at investment bank Jefferies. The goal is to optimize the capital structure and finalize the transaction before the end of the year.

The wide range of analyst price targets—from 12.90 euros to 46.00 euros, with an average near 33 euros—underscores the deep market division over the stock's fair value. Operationally, management maintains the business is running stably, projecting revenue of up to 2.4 billion euros for 2026.

The immediate task of restoring investor confidence now falls to new CFO Wolf Lehmann. The coming weeks are decisive; delivering the long-awaited audited financials will be the key trigger for the stock's next major move.